Abstract
Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 310-315 |
| Number of pages | 6 |
| Journal | Leukemia Research |
| Volume | 38 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2014 |
Fingerprint
Keywords
- CML BCR-ABL
- Minimal residual disease
- Molecular diagnostics
- Nilotinib
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Nilotinib 300mg BID as frontline treatment of CML : Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. / O'Dwyer, Michael E.; Swords, Ronan; Nagler, Arnon; McMullin, Mary Frances; le Coutre, Philipp D.; Langabeer, Stephen E.; Alvarez-Iglesias, Alberto; Fan, Hongxin; Woodman, Richard C.; Giles, Francis J.; Conneally, Eibhlin.
In: Leukemia Research, Vol. 38, No. 3, 03.2014, p. 310-315.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nilotinib 300mg BID as frontline treatment of CML
T2 - Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response
AU - O'Dwyer, Michael E.
AU - Swords, Ronan
AU - Nagler, Arnon
AU - McMullin, Mary Frances
AU - le Coutre, Philipp D.
AU - Langabeer, Stephen E.
AU - Alvarez-Iglesias, Alberto
AU - Fan, Hongxin
AU - Woodman, Richard C.
AU - Giles, Francis J.
AU - Conneally, Eibhlin
PY - 2014/3
Y1 - 2014/3
N2 - Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.
AB - Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.
KW - CML BCR-ABL
KW - Minimal residual disease
KW - Molecular diagnostics
KW - Nilotinib
UR - http://www.scopus.com/inward/record.url?scp=84894263290&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894263290&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2013.11.016
DO - 10.1016/j.leukres.2013.11.016
M3 - Article
C2 - 24333114
AN - SCOPUS:84894263290
VL - 38
SP - 310
EP - 315
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 3
ER -